Anemia Management Considering the Pathophysiology of Elderly Chronic Kidney Disease Patients

Area of Science:

• Nephrology
• Geriatrics
• Hematology

Background:

• Low hemoglobin (Hb) is linked to adverse events in chronic kidney disease (CKD) patients.
• Elderly CKD patients exhibit distinct physiological differences, including chronic inflammation and hormonal changes, impacting erythropoiesis.
• Current treatment targets and doses for anemia in elderly CKD patients are not clearly defined.

Purpose of the Study:

• To investigate the hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) and iron dysutilization in elderly CKD patients.
• To compare adverse events in elderly versus non-elderly CKD patients undergoing maintenance hemodialysis.
• To emphasize the need to consider pathophysiological characteristics before administering ESAs and iron to elderly CKD patients.

Main Methods:

• Analysis of clinical trial data comparing elderly and non-elderly CKD patients.
• Assessment of response to ESAs and iron preparations.
• Evaluation of adverse events, including cardiovascular disease, infection, hospitalization, and mortality.

Main Results:

• Elderly CKD patients may be hyporesponsive to ESAs and show dysregulated iron utilization for red blood cell production.
• Higher hemoglobin targets may not improve quality of life or survival in elderly CKD patients.
• Hyporesponsiveness to ESAs and increased intravenous iron doses are associated with adverse events in elderly hemodialysis patients.

Conclusions:

• Elderly CKD patients present unique challenges in anemia management due to age-related physiological changes.
• Standard anemia treatment protocols for younger CKD patients may not be suitable for the elderly.
• Personalized treatment strategies considering the specific pathophysiology of elderly CKD patients are crucial for optimizing outcomes and minimizing adverse events.